Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Background:
Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a
commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic
effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim
is to examine the potential antitumoral effects of tinzaparin in vivo in women with
epithelial ovarian cancer (EOC).
Study objectives:
Primary objective: The primary objective of the study is to evaluate the effects of
tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant
chemotherapy (NACT).
Secondary objectives: The secondary objective of the study is to explore the impact of
tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC
patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse
events caused by tinzaparin will be described.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Linkoeping
Collaborators:
Kalmar County Hospital Region Jönköping County Västervik Hospital